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Abstract 
Purpose: To investigate the prognostic role of vitamin D in pneumonia patients through meta-analysis. 
Methods: PubMed and Embase were systematically searched for relevant studies that assessed the 
impact of vitamin D on the risk of adverse outcomes among patients with pneumonia. Risk ratios (RR) 
with 95 % confidence intervals (95 % CI) were pooled using meta-analysis. Q-test and I2 statistics were 
used to evaluate between-study heterogeneity. 
Results: Six studies were finally included in the meta-analysis. The results of meta-analysis of these 
studies indicated that low vitamin D status was associated with higher risk of mortality among 
pneumonia patients (RR = 2.59, 95 % CI = 1.32-5.08; p = 0.005). Results from meta-analysis of studies 
with adjusted estimates suggest that low vitamin D status was independently associated with higher risk 
of mortality among pneumonia patients (RR = 3.15, 95 % CI 1.54-6.44, p = 0.002). There was no 
significant risk of bias in the meta-analysis.  
Conclusion: This study demonstrates that low vitamin D level is associated with a higher risk of 
adverse outcomes in patients with pneumonia.  
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Pneumonia is a common lung disease which is 
responsible for significant morbidity and mortality 
worldwide [1,2]. Community-acquired pneumonia 
(CAP) is the main type of pneumonia which can 
also result in high risk of mortality in critically-ill 
patients [3-5]. Risk stratification is crucial for the 
treatment of pneumonia, because it identifies 
patients with high risk of mortality for whom 
intensive care can be used [6,7]. Therefore, to 
improve the accuracy of risk stratification, there 
is need to find more appropriate factors for 
predicting the risk of mortality among pneumonia 
patients. Such findings will provide much help in 
developing some effective risk stratification tools 
for evaluating the prognosis of pneumonia 
patients [8,9]. Currently, some blood biomarkers, 
such as C-reactive protein, procalcitonin and 
proadrenomedullin are thought to be associated 
with the survival of pneumonia patients [10-12].  
 
Vitamin D plays important roles in regulating 
calcium homeostasis and immune response [13-
16]. Results from previous studies suggest that 
vitamin D has a protective effect against 
respiratory tract infections [17,18]. It has been 
suggested that vitamin D may exert immuno-
modulatory effects in patients with pneumonia 
[19,20]. Low vitamin D status or vitamin D 
deficiency is common in the elderly and in 
critically-ill patients, as well as in patients with 
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pneumonia [21-23]. Some studies reported that 
low vitamin D status was a risk factor for adverse 
outcomes among pneumonia patients, but results 
from some other studies were in disagreement 
with these reports [24-29]. Thus, in the present 
study, meta-analysis was carried out to 
quantitatively analyze published studies that 





Search strategy and selection criteria 
 
Two investigators independently performed the 
literature search, which covered PubMed and 
Embase. The key search terms were vitamin D 
or 25-hydroxyvitamin D, respiratory tract infection 
and pneumonia. No restriction on publication 
date was applied. Studies were considered 
eligible and selected if they met all the conditions 
in the selection criteria i.e., (1) the studies were 
designed to assess the role of vitamin D in 
patients with pneumonia; (2) the patients were 
diagnosed with pneumonia; (3) studies that 
compared the risk of mortality of patients with or 
without lower vitamin D level; and (4) studies with 
data on outcomes, such as hazard ratios (HR) or 
risk ratios (RR) and their 95 % confidence 
intervals (95 % CI). Studies without any one of 
these conditions were excluded. 
 
Data extraction and quality assessment 
 
Two investigators independently extracted the 
following data from original studies: name of the 
first author, country of origin, type of study, 
sample size, types of pneumonia, type of 
outcomes, confounding factors and RRs of 
mortality. Study quality was evaluated according 
to Newcastle Ottawa Scale [30]. Quality was 
defined as high level or low level by the 




STATA (Version 12.0, Stata Corporation, TX, 
USA) was used to perform statistical analyses. 
The Q-test and I2 index were used to assess 
heterogeneity. For obvious heterogeneity (I2 
more than 50 %), random-effect meta-analysis 
(DerSimonian and Laird’s method) was 
performed. For lack of heterogeneity (I2 less than 
50 %), fixed-effect meta-analysis (Mantel-
Haenszel method) was done. Sensitivity analysis 
by omitting one study at a time was applied. 
Egger test and funnel plot were used to assess 







Our database search revealed a total of 926 
articles. However, after reading the titles and 
abstracts, only 12 studies were selected and 
then scrutinized by full-text reviews [24-29, 31-
37]. Among these 13 studies, 7 studies were 
further excluded for not reporting data on the 
outcomes of interest [31-37]. Finally, 6 studies 
[24-29] fulfilled the eligibility criteria and were 
included. The characteristics of those 6 included 
studies are listed on Table 1. 
 
Three studies were retrospective cohort studies, 
and the other 3 studies were prospective cohort 
studies. The included studies published from 
1997 to 2016, and all were published in English. 
One study assessed the impact of rickets on 
mortality risk among pneumonia patients; rickets 
is associated with lack of vitamin D [24]. Five 
studies recruited adult patients, and one study 
recruited children patients. Four out of those 6 
studies recruited patients with CAP. Four studies 
provided adjusted RRs, but there were 
inconsistencies in these values. By the 
Newcastle Ottawa Scale, four studies had high 





The I2 value in the meta-analysis of the 6 studies 
was 71.4 %. Meta-analysis of these 6 studies 
showed that low vitamin D status was associated 
with higher risk of mortality among pneumonia 
patients (RR = 2.59, 95 % CI = 1.32-5.08, p = 
0.005) (Figure 1). Sensitivity analysis by omitting 
one study at a time, showed that the pooled RRs 
were not obviously changed by any single study. 
Besides, after excluding one study on the impact 
of rickets on mortality risk among pneumonia 
patients, low vitamin D status was associated 
with higher risk of mortality among pneumonia 
patients. Meta-analysis of the remaining 5 
studies also proved that low vitamin D status was 
associated with higher risk of mortality among 
pneumonia patients (RR = 3.40, 95 % CI = 1.70 - 
6.81, p = 0.001) (Figure 2). The I2 value in the 
meta-analysis of the 5 studies was 36.7 %. 
 
To assess whether low vitamin D status was an 
independent factor of mortality among 
pneumonia patients, a meta-analysis of studies 
with adjusted estimates was also performed. The 
pooled outcome suggested that low vitamin D 
status was independently associated with higher 
risk of mortality among pneumonia patients (RR 
= 3.15, 95 % CI = 54 - 6.44, p = 0.002) (Figure 
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3). The I2 value in the meta-analysis of those 5 
studies was 41.8 %. 
 
Finally, there was no significant risk of bias in the 
meta-analysis (Figure 4), and the p value for 




Vitamin D has an important role in regulating 
biological functions, including immune response 
to infections. However, the roles of vitamin D in 
pneumonia are still largely unknown [14-16]. In 
this meta-analysis, the prognostic role of vitamin 
D in pneumonia patients was analyzed. The 
findings showed that low vitamin D status was 
associated with higher risk of mortality among 
pneumonia patients. Subsequent analyses also 
found that low vitamin D status was 
independently associated with higher risk of 
mortality among pneumonia patients. Thus, 
these outcomes indicate that vitamin D plays key 
roles in the development or progression of 
pneumonia, and low vitamin D level was 
significantly associated with higher risk of 
mortality in those patients. 
 
Table 1: Characteristics of included studies on the prognostic role of vitamin D in pneumonia patients 
 
Study Study design Country Participants Confounding factors Quality 
Muhe, (1997) [24] Retrospective cohort Ethiopia 
521 children younger than 5 
years with a diagnosis of 
pneumonia 
None. Low level 
Leow (2011) [25] Prospective cohort New Zealand 
112 patients admitted with 
community acquired 
pneumonia during winter 
Sex, age, Charlson Index, 
CRP level and living in 
residential care were 
entered into the model 
High level 
Remmelts, (2012) [26] Prospective cohort Netherlands 
272 hospitalized patients 
with CAP Age and heart failure. High level 
Kim, (2015) [27] Retrospective cohort Korea 
797 patients with 
community-acquired 
pneumonia 
Pneumonia severity index. High level 
Haliloglu, (2016) [28] Retrospective cohort Turkey 
44 patients with ventilator-
associated pneumonia None. Low level 
Holter, (2016) [29] Prospective cohort Norway 






(CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein) 
 
NOTE: Weights are from random effects analysis
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Figure 1: Forest plot in the meta-analysis of total 6 included studies 
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NOTE: Weights are from random effects analysis
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Figure 2: Forest plot in the meta-analysis of five studies on the role of vitamin D in pneumonia patients 
 
NOTE: Weights are from random effects analysis
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Figure 3: Forest plot in the meta-analysis of four studies reporting adjusted risk estimates 
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Figure 4: Funnel plot in the meta-analysis of five studies on the role of vitamin D in pneumonia patients 
 
The role of vitamin D in pneumonia can be 
explained because the vitamin exerts some 
immuno-modulatory effects. Indeed, individuals 
with vitamin D deficiency have impaired immune 
function and thus are at higher risk of infections 
[38,39]. Some observational studies have found 
that patients with pneumonia usually have lower 
level of vitamin D than those without pneumonia, 
suggesting that vitamin D may be involved in 
vulnerability to pneumonia [32-34]. In the meta-
analysis carried out in this study, it was directly 
established that vitamin D is a prognostic 
biomarker in pneumonia patients. This is new 
evidence for the role of vitamin D as an important 
immuno-modulatory factor in controlling 
infections. 
 
Pneumonia is a common disease associated with 
high risk of morbidity and mortality. Risk 
stratification is crucial for the treatment of 
pneumonia. It is important to find more 
appropriate risk factors for predicting the risk of 
mortality among pneumonia patients, by 
improving the accuracy of risk stratification. The 
findings from this meta-analysis suggest that low 
vitamin D level is a good risk factor predicting the 
risk of mortality among pneumonia patients. This 
finding can be applied in clinical practice. 
 
Apart from its prognostic role, the results from 
this study also suggest possible therapeutic 
effect of vitamin D in pneumonia. Since many 
pneumonia patients have vitamin D insufficiency, 
they may be treated with vitamin D supplements. 
Several studies have assessed the association 
between vitamin D status and pneumonia, but it 
was unclear whether vitamin D supplementation 
could improve the prognosis of pneumonia 




This study had several limitations. Firstly, all the 
studies involved limited number of pneumonia 
patients. To improve the results, future studies 
with more pneumonia patients are needed. 
Secondly, some of those studies had a 
retrospective cohort design, and thus had high 
risk of bias. More studies with good quality are 
needed to provide new and strong evidence for 
the role of vitamin D in pneumonia. Thirdly, few 
studies were available, especially among African 
or Asian populations. More studies from multiple 
countries are also needed. Finally, the impact of 
season was not analyzed in most studies. 
Sunlight and seasons have important impact on 
circulating vitamin D levels and thus may have 
some influence on the survival of pneumonia 
patients. Future studies need to control the 
impact of sunlight or season when investigating 




This study demonstrates that low vitamin D level 
is associated with higher risk of adverse 
outcomes in patients with pneumonia. However, 
additional studies are needed to verify the 
prognostic role of vitamin D in pneumonia 
patients. In addition, the molecular mechanisms 
for the roles of vitamin D against infections are 








Wang et al 
Trop J Pharm Res, September 2017; 16(9): 2272  
 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Cillóniz C, Torres A, Niederman M, Eerden MVD, 
Chalmers J, Welte T, Blasi F. Community-acquired 
pneumonia related to intracellular pathogens. Intensive 
Care Med 2016; 42(9): 1374-1386. 
2. Lee JS, Giesler DL, Gellad WF, Fine MJ. Antibiotic 
Therapy for Adults Hospitalized With Community-
Acquired Pneumonia: A Systematic Review. JAMA 
2016; 315(6): 593-602. 
3. Kishaba T. Community-Acquired Pneumonia Caused by 
Mycoplasma pneumoniae: How Physical and 
Radiological Examination Contribute to Successful 
Diagnosis. Front Med 2016; 3(1):28. 
4. Phua J, Dean NC, Guo Q, Kuan WS, Lim HF, Lim TK. 
Severe community-acquired pneumonia: timely 
management measures in the first 24 hours. Critical 
Care 2016; 20(1): 237. 
5. Haq IJ, Battersby AC, Eastham K, Mckean M. 
Community acquired pneumonia in children. BMJ 2017; 
356: j686. 
6. Aoki T. Risk Stratification of Elderly Community-acquired 
Pneumonia by Adding Computed Tomography. Intern 
Med 2016; 55(5): 425-426. 
7. Kaysin A, Viera AJ. Community-Acquired Pneumonia in 
Adults: Diagnosis and Management. Am Family 
Physician 2016; 94(9): 698-706. 
8. Liapikou A, Torres A. Current treatment of community-
acquired pneumonia. Exp Opin Pharmacother 2013; 
14(10): 1319-1332. 
9. Corrales-Medina VF, Taljaard M, Fine MJ, Dwivedi G, 
Perry JJ, Musher DM, Chirinos JA. Risk stratification for 
cardiac complications in patients hospitalized for 
community-acquired pneumonia. Mayo Clin Proc 2014; 
89(1): 60-68. 
10. Florin TA, Ambroggio L. Biomarkers for Community-
Acquired Pneumonia in the Emergency Department. 
Curr Infect Dis Rep 2014; 16(12): 451. 
11. Agnello L, Bellia C, Di GM, Lo SB, Calvaruso L, Bivona 
G, Scazzone C, Dones P, Ciaccio M. Utility of serum 
procalcitonin and C-reactive protein in severity 
assessment of community-acquired pneumonia in 
children. Clin Biochem 2016; 49(1-2): 47-50. 
12. Andersen SB, Baunbæk EG, Jensen AV, Petersen PT, 
Rohde G, Ravn P. Failure of CRP decline within three 
days of hospitalization is associated with poor prognosis 
of Community-acquired Pneumonia. Infect Dis 2017: 
251-260. 
13. Bikle DD. Extraskeletal actions of vitamin D. Ann N Y 
Acad Sci 2016; 1376(1): 29-52. 
14. da Costa DS HJ, Ferreira TB, Kasahara TM, Barros PO, 
Monteiro C, et al. Vitamin D modulates different IL-17-
secreting T cell subsets in multiple sclerosis patients. J 
Neuroimmunol 2016; 299(1): 8-18. 
15. Groseanu L, Bojinca V, Gudu T, Saulescu I, Predeteanu 
D, Balanescu A, Berghea F, Opris D, Borangiu A, 
Constantinescu C, Negru M, Ionescu R. Low vitamin D 
status in systemic sclerosis and the impact on disease 
phenotype. Eur J Rheumatol 2016; 3(2): 50-55. 
16. Gonçalves de Carvalho CM, Ribeiro SM. Aging, low-
grade systemic inflammation and vitamin D: a mini-
review. Eur J Clin Nutr 2017; 71(4):434-440. 
17. Kempker JA, West KG, Kempker RR, Siwamogsatham 
O, Alvarez JA, Tangpricha V, Ziegler TR, Martin GS. 
Vitamin D Status and the Risk for Hospital-Acquired 
Infections in Critically Ill Adults: A Prospective Cohort 
Study. Plos One 2015; 10(4): e0122136. 
18. Watkins RR, Lemonovich TL, Salata RA. An update on 
the association of vitamin D deficiency with common 
infectious diseases. Can J Physiol Pharmacol 2015; 
93(5): 363-368. 
19. Borella E, Nesher G, Israeli E, Shoenfeld Y. Vitamin D: a 
new anti-infective agent? Ann N Y Acad Sci 2014; 
1317(1): 76-83. 
20. Esposito S, Lelii M. Vitamin D and respiratory tract 
infections in childhood. BMC Infect Dis 2015; 15(1): 487. 
21. Inamo Y, Hasegawa M, Saito K, Hayashi R, Ishikawa T, 
Yoshino Y, Hashimoto K, Fuchigami T. Serum vitamin D 
concentrations and associated severity of acute lower 
respiratory tract infections in Japanese hospitalized 
children. Pediatr Int 2011; 53(2): 199-201. 
22. Remmelts HH, Spoorenberg SM, Oosterheert JJ, Bos 
WJ, de Groot MC, van de Garde EM. The role of vitamin 
D supplementation in the risk of developing pneumonia: 
three independent case-control studies. Thorax 2013; 
68(11): 990-996. 
23. Sudfeld CR, Giovannucci EL, Isanaka S, Aboud S, 
Mugusi FM, Wang M, Chalamilla G, Fawzi WW. Vitamin 
D Status and Incidence of Pulmonary Tuberculosis, 
Opportunistic Infections, and Wasting Among HIV-
Wang et al 
Trop J Pharm Res, September 2017; 16(9): 2273  
 
Infected Tanzanian Adults Initiating Antiretroviral 
Therapy. J Infect Dis 2013; 207(3): 378-385. 
24. Muhe L, Lulseged S, Mason KE, Simoes EA. Case-
control study of the role of nutritional rickets in the risk of 
developing pneumonia in Ethiopian children. Lancet 
1997; 349(9068): 1801-1804. 
25. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. 
Vitamin D, innate immunity and outcomes in community 
acquired pneumonia. Respirology 2011; 16(4): 611-616. 
26. Remmelts HH, van de Garde EM, Meijvis SC, Peelen EL, 
Damoiseaux JG, Grutters JC, Biesma DH, Bos WJ, 
Rijkers GT. Addition of vitamin D status to prognostic 
scores improves the prediction of outcome in 
community-acquired pneumonia. Clin Infect Dis 2012; 
55(11): 1488-1494. 
27. Kim HJ, Jang JG, Hong KS, Park JK, Choi EY. 
Relationship between serum vitamin D concentrations 
and clinical outcome of community-acquired pneumonia. 
Int J Tuberculosis Lung Dis 2015; 19(6): 729-734. 
28. Haliloglu M, Bilgili B, Haliloglu O, Gogas YD, Cinel I. 
Vitamin D level is associated with mortality predictors in 
ventilator-associated pneumonia caused by 
Acinetobacter baumannii. J Infecti Dev Ctries 2016; 
10(6):567-574. 
29. Holter JC, Ueland T, Norseth J, Brunborg C, Frøland SS, 
Husebye E, Aukrust P, Heggelund L. Vitamin D Status 
and Long-Term Mortality in Community-Acquired 
Pneumonia: Secondary Data Analysis from a 
Prospective Cohort. PloS One 2016; 11(7): e0158536. 
30. Margulis AV, Pladevall M, Riera-Guardia N, Varas-
Lorenzo C, Hazell L, Berkman ND, Viswanathan M, 
Perez-Gutthann S. Quality assessment of observational 
studies in a drug-safety systematic review, comparison 
of two tools: the Newcastle–Ottawa Scale and the RTI 
item bank. Clin Epidemiol 2014; 6(8): 359-368. 
31. Oduwole AO, Renner JK, Disu E, Ibitoye E, Emokpae E. 
Relationship between vitamin D levels and outcome of 
pneumonia in children. West Afr J Med 2010; 29(6): 
373-378. 
32. Aregbesola A, Voutilainen S, Nurmi T, Virtanen JK, 
Ronkainen K, Tuomainen TP. Serum 25-hydroxyvitamin 
D3 and the risk of pneumonia in an ageing general 
population. J Epidemiol Community Health 2013; 67(6): 
533-536. 
33. Binks MJ, Smith-Vaughan HC, Bar-Zeev N, Chang AB, 
Andrews RM. Vitamin D insufficiency among 
hospitalised children in the Northern Territory. J Paediatr 
Child Health 2014; 50(7): 512-518. 
34. Jovanovich AJ, Ginde AA, Holmen J, Jablonski K, Allyn 
RL, Kendrick J, Chonchol M. Vitamin D Level and Risk 
of Community-Acquired Pneumonia and Sepsis. 
Nutrients 2014; 6(6): 2196-2205. 
35. Pletz MW, Terkamp C, Schumacher U, Rohde G, Schütte 
H, Welte T, Bals R. Vitamin D deficiency in community-
acquired pneumonia: low levels of 1,25(OH)2 D are 
associated with disease severity. Respir Res 2014; 
15(1): 53. 
36. Jhun BW, Kim SJ, Kim K, Lee JE, Hong DJ. Vitamin D 
Status in South Korean Military Personnel with Acute 
Eosinophilic Pneumonia: A Pilot Study. Tuberc Respir 
Dis 2015; 78(3): 232-238. 
37. Şişmanlar T, Aslan AT, Gülbahar Ö, Özkan S. The effect 
of vitamin D on lower respiratory tract infections in 
children. Türk Pediatri Arş 2016; 51(2): 94-99. 
38. Lucas RM, Gorman S, Geldenhuys S, Hart PH. Vitamin D 
and immunity. F1000prime Rep 2014; 6(6): 118. 
39. Vojinovic J, Cimaz R. Vitamin D-update for the pediatric 
rheumatologists. Pediatr Rheumatol Online J 2015; 
13(1): 18. 
40. Ali SR, Mcdevitt H. Question 1: Does vitamin D 
supplementation prevent acute lower respiratory tract 
infections in children? Arch Dis Child 2015; 100(9): 892-
895. 
41. Quraishi SA, Bittner EA, Christopher KB, Camargo CA Jr. 
Vitamin D Status and Community-Acquired Pneumonia: 
Results from the Third National Health and Nutrition 
Examination Survey. Plos One 2013; 8(11): e81120. 
42. Zhou W, Zuo X, Li J, Yu Z. Effects of nutrition intervention 
on the nutritional status and outcomes of paediatric 
patients with pneumonia. Minerva Pediatr 2016; 68(1):5-
10. 
 
